m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00346)
Target Name Complex I-AGGG (NDUFB2)
Synonyms
Complex I-AGGG; CI-AGGG; NADH-ubiquinone oxidoreductase AGGG subunit
    Click to Show/Hide
Gene Name NDUFB2
Chromosomal Location 7q34
Family complex I NDUFB2 subunit family
Function
Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.
    Click to Show/Hide
Gene ID 4708
Uniprot ID
NDUB2_HUMAN
HGNC ID
HGNC:7697
Ensembl Gene ID
ENSG00000090266
KEGG ID
hsa:4708
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
NDUFB2 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) [READER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Complex I-AGGG (NDUFB2) interacts with IGF2BP1/2/3 in NSCLC cells. circNDUFB2 participates in the degradation of IGF2BPs and activation of anti-tumor immunity during NSCLC progression via the modulation of both protein ubiquitination and degradation, as well as cellular immune responses.
Target Regulation Down regulation
Responsed Disease Non-small-cell lung carcinoma ICD-11: 2C25.Y
 Disease Info 
Pathway Response Ubiquitin mediated proteolysis hsa04120
Cell Process Tumour immunology
Ubiquitination degradation
In-vitro Model A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
BEAS-2B Normal Homo sapiens CVCL_0168
NCI-H1299 Lung large cell carcinoma Homo sapiens CVCL_0060
NCI-H1650 Minimally invasive lung adenocarcinoma Homo sapiens CVCL_1483
NCI-H1703 Lung squamous cell carcinoma Homo sapiens CVCL_1490
NCI-H1975 Lung adenocarcinoma Homo sapiens CVCL_1511
NCI-H460 Lung large cell carcinoma Homo sapiens CVCL_0459
HCC827 Lung adenocarcinoma Homo sapiens CVCL_2063
LL/2 (LLC1) Malignant tumors Mus musculus CVCL_4358
In-vivo Model A549 cells were transfected with the pZW1-FCS-circNDUFB2 plasmid or pZW1-FCS-Vector plasmid, and selected with G418 (800 ug/ml) for 4 weeks, and then 2 × 106 A549 cells were subcutaneously injected into the right flank of each mouse.
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) [READER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Complex I-AGGG (NDUFB2) interacts with IGF2BP1/2/3 in NSCLC cells. circNDUFB2 participates in the degradation of IGF2BPs and activation of anti-tumor immunity during NSCLC progression via the modulation of both protein ubiquitination and degradation, as well as cellular immune responses.
Target Regulation Down regulation
Responsed Disease Non-small-cell lung carcinoma ICD-11: 2C25.Y
 Disease Info 
Pathway Response Ubiquitin mediated proteolysis hsa04120
Cell Process Tumour immunology
Ubiquitination degradation
In-vitro Model A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
BEAS-2B Normal Homo sapiens CVCL_0168
NCI-H1299 Lung large cell carcinoma Homo sapiens CVCL_0060
NCI-H1650 Minimally invasive lung adenocarcinoma Homo sapiens CVCL_1483
NCI-H1703 Lung squamous cell carcinoma Homo sapiens CVCL_1490
NCI-H1975 Lung adenocarcinoma Homo sapiens CVCL_1511
NCI-H460 Lung large cell carcinoma Homo sapiens CVCL_0459
HCC827 Lung adenocarcinoma Homo sapiens CVCL_2063
LL/2 (LLC1) Malignant tumors Mus musculus CVCL_4358
In-vivo Model A549 cells were transfected with the pZW1-FCS-circNDUFB2 plasmid or pZW1-FCS-Vector plasmid, and selected with G418 (800 ug/ml) for 4 weeks, and then 2 × 106 A549 cells were subcutaneously injected into the right flank of each mouse.
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) [READER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Complex I-AGGG (NDUFB2) interacts with IGF2BP1/2/3 in NSCLC cells. circNDUFB2 participates in the degradation of IGF2BPs and activation of anti-tumor immunity during NSCLC progression via the modulation of both protein ubiquitination and degradation, as well as cellular immune responses.
Target Regulation Down regulation
Responsed Disease Non-small-cell lung carcinoma ICD-11: 2C25.Y
 Disease Info 
Pathway Response Ubiquitin mediated proteolysis hsa04120
Cell Process Tumour immunology
Ubiquitination degradation
In-vitro Model A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
BEAS-2B Normal Homo sapiens CVCL_0168
NCI-H1299 Lung large cell carcinoma Homo sapiens CVCL_0060
NCI-H1650 Minimally invasive lung adenocarcinoma Homo sapiens CVCL_1483
NCI-H1703 Lung squamous cell carcinoma Homo sapiens CVCL_1490
NCI-H1975 Lung adenocarcinoma Homo sapiens CVCL_1511
NCI-H460 Lung large cell carcinoma Homo sapiens CVCL_0459
HCC827 Lung adenocarcinoma Homo sapiens CVCL_2063
LL/2 (LLC1) Malignant tumors Mus musculus CVCL_4358
In-vivo Model A549 cells were transfected with the pZW1-FCS-circNDUFB2 plasmid or pZW1-FCS-Vector plasmid, and selected with G418 (800 ug/ml) for 4 weeks, and then 2 × 106 A549 cells were subcutaneously injected into the right flank of each mouse.
Lung cancer [ICD-11: 2C25]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary Complex I-AGGG (NDUFB2) interacts with IGF2BP1/2/3 in NSCLC cells. circNDUFB2 participates in the degradation of IGF2BPs and activation of anti-tumor immunity during NSCLC progression via the modulation of both protein ubiquitination and degradation, as well as cellular immune responses.
Responsed Disease Non-small-cell lung carcinoma [ICD-11: 2C25.Y]
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
Target Regulation Down regulation
Pathway Response Ubiquitin mediated proteolysis hsa04120
Cell Process Tumour immunology
Ubiquitination degradation
In-vitro Model A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
BEAS-2B Normal Homo sapiens CVCL_0168
NCI-H1299 Lung large cell carcinoma Homo sapiens CVCL_0060
NCI-H1650 Minimally invasive lung adenocarcinoma Homo sapiens CVCL_1483
NCI-H1703 Lung squamous cell carcinoma Homo sapiens CVCL_1490
NCI-H1975 Lung adenocarcinoma Homo sapiens CVCL_1511
NCI-H460 Lung large cell carcinoma Homo sapiens CVCL_0459
HCC827 Lung adenocarcinoma Homo sapiens CVCL_2063
LL/2 (LLC1) Malignant tumors Mus musculus CVCL_4358
In-vivo Model A549 cells were transfected with the pZW1-FCS-circNDUFB2 plasmid or pZW1-FCS-Vector plasmid, and selected with G418 (800 ug/ml) for 4 weeks, and then 2 × 106 A549 cells were subcutaneously injected into the right flank of each mouse.
References
Ref 1 circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021 Jan 12;12(1):295. doi: 10.1038/s41467-020-20527-z.